Psychiatry, psychopharmacology and P-450s

Human Psychopharmacology

Volumn 11, Issue 2, 1996, Pages 97-114

  Glue, Paul ^a   Banfield, Christopher ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

antidepressants; antiepileptics; anxiolytics; cytochrome P450; drug interactions; drug metabolism; neuroleptics

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; LOXAPINE; MIDAZOLAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; THIORIDAZINE; TIOTIXENE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; DRUG BINDING; DRUG EFFECT; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL;

EID: 0030003604     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199603)11:2<97::AID-HUP759>3.0.CO;2-7     Document Type: Article

References (187)

1. Agundez, J. A. G., Ledesma, M. C., Ladero, J. M. and Benitez, J. (1995). Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clinical Pharmacology and Therapeutics, 57, 265-269.
2. Ahsan, C. H., Renwick, A. G., Waller, D. G., Challenor, V. F., George, C. F. and Amanullah, M. (1993). The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clinical Pharmacology and Therapeutics, 54, 329-338.
3. Alderman, J., Greenblatt, D. J., Allison, J., Chung, M. and Harrison, W. (1994). Desipramine pharmacokinetics with the serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline. Neuropsychopharmacology, 10 (suppl 3 part 2), 263S.
4. Anderson, G. D. (1989). Phenobarbital: biotransformation. In: Antiepileptic Drugs, 3rd edn, Levy, R., et al. (Eds), Raven Press, New York, pp. 305-312.
5. Andersson, T., Miners, J. O. and Birkett, D. J. (1994). Diazepara metabolism by human liver microsomes is mediated by both s-mephenytoin hydroxylase and CYP3A isoforms. Clinical Pharmacology and Therapeutics, 55, 138.
6. Arana, G. W., Epstein, S., Molloy, M. and Greenblatt, D. J. (1988). Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. Journal of Clinical Psychiatry, 49, 448-449.
7. Aranow, R. B., Hudson, J. I., Pope, H. G., Grady, T. A., Laage, T. A., Bell, I. R. and Cole, J. O. (1989). Elevated antidepressant plasma levels after addition of fluoxetine. Americal Journal of Psychiatry, 146, 911-913.
8. Bailey, D. G., Arnold, J. M. O. and Spence, J. D. (1994). Grapefruit juice and drugs. Clinical Pharmacokinetics, 26, 91-98.
9. Bajpai, M., Roskos, L. K., Shen, D. D., Trager, W. F. and Levy, R. H. (1994). Role of s-mephenytoin hydroxylase in the metabolism of phenytoin. Pharmaceutical Research, 11 (suppl), S-438.
10. Balant-Gorgia, A. E., Balant, L. P. and Garrone, G. (1989). High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Therapeutic Drug Monitoring, 11, 415-420.
11. Baldessarini, R. J., Teicher, M. H., Cassidy, J. W. and Stein, M. H. (1988). Anticonvulsant co-treatment may increase toxic metabolites of antidepressants and other psychotropic drugs. Journal of Clinical Psychopharmacology, 8, 381-382.
12. Barzaghi, N., Gatti, G., Crema, F., Monteleone, M., Amione, C., Leone, L. and Perucca, E. (1987). Inhibition of erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. British Journal of Clinical Pharmacology, 24, 836-838.
13. Baumann, P., Jonzier-Perey, M., Koeb, L., Kupfer, A., Tinguely, D. and Schopf, J. (1986). Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. International Clinical Psychopharmacology, 1, 102-112.
14. Baumann, P., Meyer, J. W., Amey, M., Baettig, D., Bryois, C., Jonzier-Perry, M., Koeb, L., Monney, C. and Woggon, B. (1992). Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Therapeutic Drug Monitoring, 14, 1-8.
15. Benitez, J., Carrillo, J. A. and Herraiz, A. G. (1994). Higher incidence of side-effects in psychiatric patients poor metabolizers of debrisoquine. Clinical Pharmacology and Therapeutics, 55, 170.
16. Bergstrom, R. F., Lemberger, L., Cerimele, B. J., Wolen, L. R. and Kisicki, J. C. (1990). Relative bioequivalence of a fluoxetine oral solution versus the marketed capsule. Pharmaceutical Research, 7 (suppl.), S-251.
17. Bergstrom, R. F., Peyton, A. L. and Lemberger, L. (1992). Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapeutics, 51, 239-248.
18. Bertilsson, L., Aberg-Wistedt, A., Gustafsson, L. L. and Nordin, C. (1985). Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Therapeutic Drug Monitoring, 7, 478-480.
19. Bertilsson, L., Aberg-Wistedt, A., Liden, A., Otani, K. and Spina, E. (1988). Alprazolam does not inhibit the metabolite of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. Therapeutic Drug Monitoring, 10, 231-233.
20. Bertilsson, L., Carillo, J. A., Dahl, M-L., Llerena, A., Aim, C., Bondesson, U., Lindstrom, L., de la Rubia, I. R., Ramos, S. and Benitez, J. (1994). Clozapine disposition covaries with CYP1A2 activity as determined by a caffeine test. British Journal of Clinical Pharmacology, 38, 471-473.
21. Bertilsson, L., Dahl, M-L., Sjoqvist, F., Aberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., Ingelman-Sundberg, M. (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341, 63.
22. Bertilsson, L., Eichelbaum, M., Mellstrom, B., Sawe, J., Schulz, H.-U and Sjoqvist, F. (1980). Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sciences, 27, 1673-1677.
23. Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Sawe, J. and Villen, T. (1989). Importance of genetic factors in the regulation of diazepam metabolism: relationship to s-mephenytoin, but not debrisoquine hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348-355.
24. Bertilsson, L., Lou, Y-Q., Du, Y-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L. and Sjoqvist, F. (1992). Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and s-mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
25. Bertilsson, L., Mellstrom, B., Sjoqvist, F., Martensson, B. and Asberg, M. (1981). Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet, i, 560-561.
26. Bertschy, G., Vandel, S., Vandel, B., Allers, G. and Volmat, R. (1991). Fluvoxamine-tricyclic antidepressant interaction. European Journal of Clinical Pharmacology, 40, 119-120.
27. Bloomer, J. C., Woods, F. R., Haddock, R. E., Lennard, M. S. and Tucker, G. T. (1992). The role of human cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. British Journal of Clinical Pharmacology, 33, 521-523.
28. Breyer-Pfaff, U., Pfandl, B., Nill, K., Nusser, E., Monney, C., Jonzier-Perry, M., Baettig, D., Baumann, P. (1992). Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 enzymes. Clinical Pharmacology and Therapeutics, 52, 350-358.
29. Brosen, K. (1993). The pharmacogenetics of the selective serotonin reuptake inhibitors. Clinical Investigations, 71, 1002-1009.
30. Brosen, K. and Gram, L. F. (1989). Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. European Journal of Clinical Pharmacology, 37, 155-160.
31. Brosen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H. and Gram, L. F. (1993a). Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. European Journal of Clinical Pharmacology, 44, 349-355.
32. Brosen, K. and Kragh-Sorensen, P. (1992). Concomitant intake of nortriptyline and carbamazepine. Therapeutic Drug Monitoring, 15, 258-260.
33. Brosen, K., Otton, S. V. and Gram, L. F. (1986). Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics, 40, 543-549.
34. Brosen, K., Skjelbo, E., Rasmussen, B., Poulsen, H. E. and Loft, S. (1993b). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology, 45, 1211-1214.
35. Brown, C. S., Wells, B. G., Cold, J. A., Froemming, J. H., Self, T. H. and Jabbour, J. T. (1990). Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology, 10, 359-362.
36. Buch, A., Shikla, U., Pitman, K. and Barbhaiya, R. (1993). Pharmacokinetics of nefazodone in extensive and poor metabolizers of dextromethorphan. Pharmaceutical Research, 10 (suppl.), S-314.
37. Centorrino, F., Baldessarini, R. J., Kando, J., Frankenburg, F. R., Volpicelli, S. A., Puopolo, P. R. and Flood, J. G. (1994). Serum concentrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine and valproate. American Journal of Psychiatry, 151, 123-125.
38. Chang, T. K. H., Weber, G. F., Crespi, C. L. and Waxman, D. J. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research, 53, 5629-5637.
39. Chen. S., King, V., Wedlund, P. J. and Hays, L. (1995). Cytochrome P450-2D6 (CYP2D6): simplified screening for the A and B alleles and deficient enzyme expression. Clinical Pharmacology and Therapeutics, 57, 150.
40. Cholerton, S., Daly, A. K. and Idle, J. R. (1992). The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological Sciences, 13, 434-439.
41. Collins, J. M. (1995). Utility of in vitro metabolism data in the drug evaluation/review process. Symposium, Integration of in vitro human drug metabolism into drug development. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego.
42. Crewe, H. K., Lennard, M. S., Tucker, G. T., Woods, F. R. and Haddock, R. E. (1992). The effect of selective serotonin reptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262-265.
43. Dahl, M-L. and Bertilsson, L. (1993). Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics, 3, 61-70.
44. Dahl, M-L., Ekqvist, B., Widen, J. and Bertilsson, L. (1991). Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatrica Scandinavica, 84, 99-100.
45. Dahl, M-L., Johansson, I., Palmertz, M. P., Ingleman-Sundberg, M. and Sjoqvist, F. (1992). Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clinical Pharmacology and Therapeutics, 51, 12-17.
46. Dahl, M-L., Llerena, A., Bondesson, U., Lindstrom, L. and Bertilsson, L. (1994). Disposition of clozapine in man: lack of association with debrisoquine and s-mephenytoin hydroxylation polymorphisms. British Journal of Clinical Pharmacology, 37, 71-74.
47. Dahl-Puustinen, M-L., Liden, A., Aim, C., Nordin, C. and Bertilsson, L. (1989). Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in human beings. Clinical Pharmacology and Therapeutics, 46, 78-81.
48. DeVane, C. L. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55 (suppl. 12), 38-45.
49. Doshi, B. S., Kulkarni, R. D., Chauhan, B. L. and Wilkinson, G. L. (1990). Frequency of impaired mephenytoin hydroxylation in an Indian population. British Journal of Clinical Pharmacology, 30, 779-780.
50. Downs, J. M., Downs, A. D., Rosenthal, T. L., Deal, N. and Akiskal, H. S. (1989). Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. Journal of Clinical Psychiatry, 50, 226-227.
51. Drake, W. M. and Gordon, G. D. (1994). Heart block in a patient on propranolol and fluoxetine. Lancet, 343, 425-426.
52. Eichelbaum, M. (1982). Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics, 7, 1-22.
53. Ereshefsky, L., Jann, M. W., Saklad, S. R., Davis, C. M., Richards, A. L. and Burch, N. R. (1985). Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biological Psychiatry, 20, 329-352.
54. Ereshefsky, L., Reisenmann, C. and Lam, Y. W. F. (1995). Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clinical Pharmacokinetics, 29 (suppl. 1), 10-19.
55. Ereshefsky, L., Saklad, S. R., Watanabe, M. D., Davis, C. M. and Jann, M. W. (1991). Thiothixine pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors and demographic variables. Journal of Clinical Psychopharmacology, 11, 296-301.
56. Fischer, V., Vogels, B., Maurer, G. and Tynes, R. E. (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapy, 260, 1355-1360.
57. Fleishaker, J. C. and Hulst, L. K. (1992). Effects of fluvoxamine on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Pharmaceutical Research, 9 (suppl.), S-292.
58. Ford, J. M., Truman, C. A., Wilcock, G. K. and Roberts, C. J. (1993). Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clinical Pharmacology and Therapeutics, 53, 691-695.
59. Fritze, J., Unsorg, B. and Lanczik, M. (1991). Interaction between carbamazepine and fluvoxamine. Acta Psychiatrica Scandinavica, 84, 583-584.
60. Gammans, R. E., Mayol, R. F. and Labudde, J. A. (1986). Metabolism and disposition of buspirone. American Journal of Medicine, 80 (suppl. 3B), 41-51.
61. Garfinkel, D. (1958). Studies on pig liver microsomes. 1. Enzymic and pigment composition of different microsomal fractions. Archives of Biochemistry and Biophysics, 77, 493-509.
62. Goff, D. C., Henderson, D. C. and Amico, E. (1992). Cigarette smoking in schizophrenia: relationship to psychopathology and medication side-effects. American Journal of Psychiatry, 149, 1189-1194.
63. Goff, D. C., Midha, K. K., Brotman, A. W., McCormick, S., Waites, M. and Amico, E. T. (1991a). An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of Clinical Psychopharmacology, 11, 193-197.
64. Goff, D. C., Midha, K. K., Brotman, A. W., Waites, M. and Baldessarini, R. J. (1991b). Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. American Journal of Psychiatry, 148, 790-792.
65. Goff, D. C., Midha, K. K., Sarid-Segal, O., Hubbard, J. W. and Amico, E. (1995). An placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology, 117, 417-423.
66. Gonzales, F. J. and Korzekwa, K. R. (1995). Cytochromes P450 expression systems. Annual Review of Pharmacology and Toxicology, 35, 369-390.
67. Gram, L. F., Brosen, K. and the Danish University Antidepressant Group (1993a). Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. British Journal of Clinical Pharmacology, 35, 649-652.
68. Gram, L. F., Debruyne, D., Caillard, V., Boulenger, J. P., Lacotte, J., Moulin, M. and Zarifian, E. (1989). Substantial rise in sparteine metabolic ratio during haloperidol treatment. British Journal of Clinical Pharmacology, 27, 272-275.
69. Gram, L. F., Guentert, T. W., Grange, S., Vistisen, K. and Brosen, K. (1995). Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clinical Pharmacology and Therapeutics, 57, 670-677.
70. Gram, L. F., Hansen, M. G. J., Sindrup, S. H., Brosen, K., Poulsen, J. H., Aaes-Jorgensen, T. and Overo, K. (1993b). Citalopram: interaction studies with levomepromazine, imipramine and lithium. Therapeutic Drug Monitoring, 15, 18-24.
71. Gram, L. F. and Overo, K. F. (1972). Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. British Medical Journal, i, 463-465.
72. Grasela, T. H., Antal, E. J., Ereshefsky, L., Wells, B. G., Evans, R. L. and Smith, R. B. (1987). An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clinical Pharmacology and Therapeutics, 42, 433-441.
73. Greenblatt, D. J., Preskorn, S. H., Cotreau, M. M., Horst W. D. and Harmatz, J. S. (1992). Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics, 52, 479-486.
74. Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Harrel, L. M., Tobias, S., Shader, R. I. and Wright, C. E. (1995). Interaction of triazolam and ketoconazole. Lancet, 345, 191.
75. Greene, D. S., Dockens, R. C., Salazar, D. E. and Barbhaiya, R. H. (1994). Coadministration of nefazodone and benzodiazepines: pharmacokinetic assessment. Clinical Pharmacology and Therapeutics, 55, 141.
76. Grimsley, S. R., Jann, M. W., Carter, J. G., D'Mello, A. P. and D'Souza, M. J. (1991). Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical Pharmacology and Therapeutics, 50, 10-15.
77. Guengerich, F. P. (1990). Mechanism-based inactivation of human liver microsomal cytochrome P450 IIIA4 by gestodene. Chemical Research and Toxicology, 3, 363-371.
78. Guentert, T. W., Gram, L. F., Grange, S. and Brosen, K. (1994). Reversible interaction of moclobemide with CYP2D6 and CYP2C9. Clinical Pharmacology and Therapeutics, 55, 137.
79. Hammer, W. and Sjoqvist, F. (1967). Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sciences, 6, 1895-1903.
80. Harvey, A. T. and Preskorn, S. H. (1995). Interactions of serotonin reptake inhibitors with tricyclic antidepressants. Archives of General Psychiatry, 52, 783-784.
81. Heim, M. and Meyer, U. A. (1990). Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
82. Henauer, S. A. and Hollister, L. E. (1984). Cimetidine interaction with imipramine and nortriptyline. Clinical Pharmacology and Therapeutics, 35, 183-187.
83. Hong, J., Pan, J., Gonzales, F. J., Gelboin, H. V. and Yang, C. S. (1987). The induction of a specific form of cytochrome P450 (P-450j) by fasting. Biochemical and Biophysical Research Communications, 142, 1077-1083.
84. Honig, P. K., Wortham, D. C., Zamani, K., Conner, D. P., Mullin, J. C. and Cantilena, L. R. (1993). Terfenadine ketoconazole interaction. Journal of the American Medical Association, 269, 1513-1518.
85. Horsmans, Y., Desager, J. P. and Harvengt, C. (1992). Absency of CYP3A genetic polymorphism assessed by urinary excretion of 6-β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacology and Toxicology, 71, 258-261.
86. Huang, M-L., van Peer, A., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z. and Jonkman, J. H. G. (1993). Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clinical Pharmacology and Therapeutics, 54, 257-268.
87. Hunt, C. M., Westerkam, W. R. and Stave, G. M. (1992). Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology, 44, 275-283.
88. Hussain, M. S., Coutts, R. T., Baker, G. B., Daneshtalab, M. and Micetich, R. G. (1992). Selective inhibition of trimipramine metabolism by quinidine in the rat. Pharmaceutical Research, 9 (suppl.), S-297.
89. Inaba, T., Jurima, M., Mahon, W. A. and Kalow, W. (1985). In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Drug Metabolism and Disposition, 13, 443-448.
90. Ishida, M., Otani, K., Mihara, K., Yasui, N., Kondo, T., Osanai, T., Ohkubo, T., Sugawara, K., Kaneko, S. and Fukushima, Y. (1994). Steady state plasma kinetics of trazondone and m-chlorophenylpiperazine. Neuropsychopharmacology, 10 (suppl. 3 part 2), 262S.
91. Janicak, P. G., Javaid, J. I., Sharma, R. P., Comaty, J. E., Peterson, J. and Davis, J. M. (1989). Trifiuoperazine plasma levels and clinical response. Journal of Clinical Psychopharmacology, 9, 340-346.
92. Jann, M. W., Archer, D., Nuyen, N., Pollock, S. H. and D'Souza, M. J. (1990). Cyclosporine-azapirone drug interaction. Pharmaceutical Research, 7 (suppl.), S-253.
93. Jann, M. W., Saklad, S. R., Ereshefsky, L., Richards, A. L., Harrington, C. A. and Davis, C. M. (1986). Effects of smoking on haloperidol and reduced haloperidol concentrations and haloperidol clearance. Psychopharmacology, 90, 468-470.
94. Jerling, M., Lindstrom, L., Bondesson, U. and Bertilsson, L. (1994). Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16, 368-374.
95. Johnson, C. M., Thummel, K. E., Kroetz, D. L., Korzekwa, K. R., Gonzalez, F. J., Kerr, B. M. and Levy, R. H. (1992). Metabolism of carbamazepine by cytochrome P450 isoforms 3A4, 2C8 and 1A2. Pharmaceutical Research, 9 (suppl.), S-301.
96. Kallio, J., Huupponen, R., Seppala, Sako, E. and Iisalo, E. (1990). The effects of β-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. British Journal of Clinical Pharmacology, 30, 638-643.
97. Kapetanovic, I. M., Kupferberg, H. J., Porter, R. J., Theodore, W., Schulman, E. and Penry, J. K. (1981). Mechanism of valproate-phenobarbital interaction in epileptic patients. Clinical Pharmacology and Therapeutics, 29, 480-486.
98. Kappas, A., Alvares, A. P., Anderson, K. E., Pantuck, E. J., Pantuck, C. B., Chang, R. and Conney, A. H. (1978). Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clinical Pharmacology and Therapeutics, 23, 445-450.
99. Kappas, A., Anderson, K. E., Conney, A. H. and Alvares, A. P. (1976). Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics, 20, 643-653.
100. Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D L., Gonzalez, F. J. and Levy, R. H. (1994). Human liver carbamazepine metabolism. Biochemical Pharmacology, 7, 1969-1979.
101. Ketter, T. A., Post, R. M. and Worthington, K. (1991). Principles of clinically important drug interactions with carbamazepine. Part 1. Journal of Clinical Psychopharmacology, 11, 198-203.
102. Kidron, R., Averbuch, I., Klein, E. and Belmaker, R. H. (1985). Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry, 20, 219-222.
103. Koop, D. R. (1992). Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal, 2, 724-730.
104. Kramer Neilsen, K., Brosen, K., Gram, L. F., and the Danish University Antidepressant Group (1992). Steady state plasma concentrations of clomipramine and its metabolites: impact on the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 43, 405-411.
105. Kramer Neilsen, K., Brosen, K., Jeppe Hansen, M. G. and Gram, L. F. (1994). Single dose kinetics of clomipramine: relationship to the sparteine and s-mephenytoin oxidation polymorphisms. Clinical Pharmacology and Therapeutics, 55, 518-527.
106. Krishna, D. R. and Klotz, U. (1994). Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics, 26, 144-160.
107. Kronbach, T., Mathys, D., Umeno, M., Gonzales, F. J. and Meyer, U. A. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
108. Kudriakova, T. B., Sirota, L. A., Rozova, G. I. and Gorkov, V. A. (1992). Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. British Journal of Clinical Pharmacology, 33, 611-615.
109. Lasher, T. A., Fleishaker, J. C., Steenwyk, R. C. and Antal, E. J. (1991). Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology, 104, 323-327.
110. Leinonen, E., Lillsunde, P., Laukkanen, V. and Ylitalo, P. (1991). Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. Journal of Clinical Psychopharmacology, 11, 313-318.
111. Lemberger, L., Rowe, H., Bosomworth, J. C., Tenbarge, J. B. and Bergstrom, R. F. (1988). The effects of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics, 43, 412-419.
112. Lemoine, A., Gautier, J. C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P. and Leroux, P. J. P. (1993). Major pathways of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Molecular Pharmacology, 43, 827-832.
113. Llerena, A., Aim, C., Dahl, M-L., Ekqvist, B. and Bertilsson, L. (1992). Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Therapeutic Drug Monitoring, 14, 92-97.
114. Lown, K. S., Thummel, K. E., Benedict, P. E., Shen, D. D., Turgeon, D. K., Berent, S. and Watkins, P. B. (1995). The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16-24.
115. Martinelli, V., Bocchetta, A., Palmas, A. M. and del Zompo, M. (1993). An interaction between carbamazepinc and fluvoxamine. British Journal of Clinical Pharmacology, 36, 613-616.
116. Mattson, R. H. and Cramer, J. A. (1989). Valproate: interactions with other drugs. In: Antiepileptic Drugs, 3rd edn, Levy, R., et al. (Eds), Raven Press, New York, pp. 621-632.
117. May, D. G., Wilkinson, G. R. and Branch, R. A. (1994). Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clinical Pharmacology and Therapeutics, 55, 492-500.
118. Mellstrom, B., Bertilsson, L., Lou, Y.-C., Sawe, J. and Sjoqvist, F. (1983). Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clinical Pharmacology and Therapeutics, 34, 516-520.
119. Mellstrom, B., Bertilsson, L., Sawe, J., Schulz, H. U. and Sjoqvist, F. (1981). E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clinical Pharmacology and Therapeutics, 30, 189-193.
120. Mellstrom, B., Sawe, J., Bertilsson, L. and Sjoqvist, F. (1986). Amitriptyline metabolism: association with debrisoquine hydroxylation in nonsmokers. Clinical Pharmacology and Therapeutics, 39, 369-371.
121. Meyer, J. W., Woggon, B., Baumann, P. and Meyer, U. A. (1990). Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. European Journal of Clinical Pharmacology, 39, 613-614.
122. Murray, M. (1992). P450 enzymes. Clinical Pharmacokinetics, 23, 132-146.
123. Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R. and Branch, R. A. (1985). Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and European populations. Clinical Pharmacology and Therapeutics, 38, 402-408.
124. Nebert, D. W. and Gonzales, F. J. (1987). P450 genes: structure, evolution and regulation. Annual Review of Biochemistry, 56, 945-993.
125. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyerelsen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K. and Nebert, D. W. (1993). The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12, 1-51.
126. Nightingale, S. L. (1994). Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. Journal of the American Medical Association, 271, 1067.
127. Ohmori, S., Takeda, S., Rikihisi, T., Kiuchi, M., Kanakubo, Y. and Kitada, M. (1993). Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biological and Pharmaceutical Bulletin, 16, 571-575.
128. Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J. J. and Nenvonen, P. J. (1993). A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298-305.
129. Olkkola, K. T., Backman, J. T. and Neuvonen, P. J. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 55, 481-485.
130. Omura, T. and Sato, R. (1962). A new cytochrome in liver microsomes. Journal of Biological Chemistry, 237, PC1375-PC1376.
131. Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T. and Sellers, E. M. (1994). Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT reptake inhibitors. Clinical Pharmacology and Therapeutics, 55, 141.
132. Otton, S. V., Inaba, T. and Kalow, W. (1983). Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sciences, 32, 795-800.
133. Otton, S. V., Wu, D., Joffe, R. T., Cheung, S. W. and Sellers, E. M. (1993). Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clinical Pharmacology and Therapeutics, 53, 401-409.
134. Perault, M. C., Griesemann, E., Bouquet, S., Lavoisy, J. and Vandel, B. (1989). A study of the interaction of viloxazine with theophylline. Therapeutic Drug Monitoring, 11, 520-522.
135. Perrot, N., Nalpas, B., Yang, C. S. and Beaune, P. H. (1989). Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. European Journal of Clinical Pharmacology, 19, 549-555.
136. Perucca, E., Gatti, G. and Spina, E. (1994). Clinical pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics, 27, 175-190.
137. Piccirilli, G., Caille, G. and Vezina, M. (1993). Biotransformation of loxapine in two animal models of the human debrisoquine polymorphism. Pharmaceutical Research, 10 (suppl.), S325.
138. Pisani, F., Fazio, A., Oteri, G., Perucca, E., Russo, M., Trio, R., Pisani, B. and Di Perri, R. (1986). Carbamazepine-viloxazine interaction in patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 49, 1142-1145.
139. Popli, A., Baldessarini, R. J. and Cole, J. O. (1995). Interactions of serotonin reptake inhibitors with tricyclic antidepressants - in reply. Archives of General Psychiatry, 52, 784-785.
140. Potkin, S. G., Shen, Y., Pardes, H., Phelps, B. H., Zhou, D., Shu, L., Korpi, E. and Wyatt, R. J. (1984). Haloperidol concentrations elevated in Chinese patients. Psychiatry Research, 12, 167-172.
141. Preskorn, S. H. (1993). Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Journal of Clinical Psychiatry, 54 (suppl. 9), 14-34.
142. Preskorn, S. H., Alderman, J., Chung, M., Harrison, W., Messig, M. and Harris, S. (1994). Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology, 14, 90-98.
143. Preskorn, S. H. and Magnus, R. D. (1994). Inhibition of hepatic P-450 isoenzymes by selective serotonin reptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacology Bulletin, 20, 251-259.
144. Price, L. H., Goddard, A. W., Barr, L. C. and Goodman, W. K. (1995). Pharmacological challenges in anxiety disorders. In: Psychopharmacology: the Fourth Generation of Progress, Bloom, F. E. and Kupfer, D. J. (Eds), Raven Press, New York, pp. 1311-1323.
145. Raitasuo, V., Lehtovaara, R. and Huttunen, M. (1993). Carbamazepine and plasma levels of clozapine. American Journal of Psychiatry, 150, 169.
146. Raitasuo, V., Lehtovaara, R. and Huttunen, M. (1994). Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: a case report. Psychopharmacology, 116, 115-116.
147. Rasmussen, B. B., Maenpaa, J., Pelkonen, O., Loft, S., Poulsen, H. E., Lykkesfeldt, J. and Brosen, K. (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. British Journal of Clinical Pharmacology, 39, 151-159.
148. Ratanasavanh, D., Beaune, P., Morel, F., Flinois, J.-P., Guengerich, F. P. and Guillouzo, A. (1991). Intralobular distribution and quantitation of cytochrome P450 enzymes in human liver as a function of age. Hepatology, 13, 1142-1151.
149. Reidenberg, P., Glue, P., Banfield, C., Colucci, R. D., Meehan, J. W., Radwanski, E., Mojavarian, P., Lin, C. C., Nazamis, J., Guillaume, M. and Affrime, M. (1995). Effects of felbamate on multiple dose pharmacokinetics of phenobarbital. Clinical Pharmacology and Therapeutics, 58, 279-287.
150. Relling, M. V., Lin, J-S., Ayers, G. D. and Evans, W. E. (1992). Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clinical Pharmacology and Therapeutics, 52, 643-658.
151. Rodrigues, A. D. (1994). Use of in vitro human metabolism studies in drug development. Biochemical Pharmacology, 48, 2147-2156.
152. Rudorfer, M. V., Lane, E. A., Chang, W-H., Zhang, M. and Potter, W. Z. (1984). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. British Journal of Clinical Pharmacology, 17, 433-440.
153. Schmider, J., Greenblatt, D. J., von Moltke, L. L. and Shader, R. I. (1995). N-demethylation of amitriptyline in vitro: role of CYP3A isoforms. Clinical Pharmacology and Therapeutics, 57, 193.
154. Schuetz, J. D., Beach, D. L. and Guzelian, P. S. (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4, 11-20.
155. Sindrup, S. H., Brosen, K., Gram, L. K., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G. and Zussman, B. D. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 51, 278-287.
156. Sindrup, S. H., Brosen, K., Hansen, M. G. J., AaesJorgensen, T., Overo, K. F. and Gram, L. F. (1993). Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic Drug Monitoring, 15, 11-17.
157. Skjelbo, E. and Brosen, K. (1992). Inhibitors of imipramine metabolism by human liver microsomes. British Journal of Clinical Pharmacology, 34, 256-261.
158. Skjelbo, E., Brosen, K., Hallas, J. and Gram, L. F. (1991). The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical Pharmacology and Therapeutics, 49, 18-23.
159. Sperber, A. D. (1991). Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety, 6, 460-462.
160. Spina, E., Avenoso, A., Campo, G., Caputi, A. P. and Perucca, E (1994).
161. Spina, E., Avenoso, A., Campo, G. M., Caputi, A. P. and Perucca, E. (1995). The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology, 117, 413-416.
162. Spina, E., Ancione, M., Di Rosa, A. E., Meduri, M. and Caputi, A. P. (1992a). Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. European Journal of Clinical Pharmacology, 42, 347-348.
163. Spina, E., Campo, G. M., Avenoso, A., Pollicino, M. A. and Caputi, A. P. (1992b). Interaction between fluvoxamine and imipramine/desipramine in four patients. Therapeutic Drug Monitoring, 14, 194-196.
164. Spina, E., Martines, C., Caputi, A. P., Cobaleda, J., Pinas, B., Carillo, J. A. and Benitez, J. (1991). Debrisoquine oxidation phenotype during neuroleptic monotherapy. European Journal of Clinical Pharmacology, 41, 467-470.
165. Spina, E., Pollicino, A. M., Avenoso, A., Campo, G. M., Perucca. E. and Caputi, A. P. (1993). Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Therapeutic Drug Monitoring, 15, 243-246.
166. Stimmel, G. L. and Falloon, I. R. H. (1983). Chlorpromazine plasma levels, adverse effects and tobacco smoking: case report. Journal of Clinical Psychiatry, 44, 420-422.
167. Syvalahti, E. K. G., Lindberg, R., Kallio, J. and de Vocht, M. (1986). Inhibitory effects of neuroleptics on debrisoquine oxidation in man. British Journal of Clinical Pharmacology, 22, 89-92.
168. Vaughan, D. A. (1988). Interaction of fluoxetine with tricyclic antidepressants. American Journal of Psychiatry, 145, 1478.
169. Vesell, E. S., Passananti, G. T. and Greene, F. E. (1970). Impairment in drug metabolism in man by allopurinol and nortriptyline. New England Journal of Medicine, 283, 1484-1488.
170. Vinarova, E., Vinar, O. and Kalvach, Z. (1984). Smokers need higher doses of neuroleptic drugs. Biological Psychiatry, 19, 1265-1268.
171. von Bahr, C., Movin, G., Nordin, C., Liden, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H. and Sjoqvist, F. (1991). Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 49, 234-240.
172. von Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S. and Shader, R. I. (1994a). Inhibition of desipramine hydroxylation in vitro by serotonin reuptake inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278-1283.
173. von Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Harmatz, J. S. and Shader, R. I. (1994b). Inhibitors of alprazolam metabolism by serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
174. von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S. and Shader, R. I. (1995). Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychopharmacology, 15, 125-131.
175. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Wright, C. E., Harmatz, J. S. and Shader, R. I. (1994c). Triazolam hydroxylation in vitro: species differences and metabolic inhibition. Clinical Pharmacology and Therapeutics, 55, 179.
176. von Moltke, L. L., Greenblatt, D. J., Harmatz, L. S. and Shader, R. I. (1994d). Cytochromes in psychopharmacology. Journal of Clinical Psychopharmacology, 14, 1-4.
177. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Harmatz, J. S. and Shader, R. I. (1995). Metabolism of drugs by cytochrome P450 3A isoforms. Clinical Pharmacokinetics, 29 (suppl. 1), 33-44.
178. Walley, T., Pirmohamed, M., Proudlove, C. and Maxwell, D. (1993). Interaction of metoprolol and fluoxetine. Lancet, 341, 967-968.
179. Watkins, P. B. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Seminars in Liver Disease, 10, 235-250.
180. Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A. and Guzelian, P. S. (1989). Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Journal of Clinical Investigation, 83, 688-697.
181. Wrighton, S. A. (1995). Examples of the impact of in vitro human drug metabolism data on drug development decisions. Symposium, Integration of in vitro human drug metabolism into drug development. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego.
182. Wrighton, S. A. and Stevens, J. C. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
183. Yang, C. S., Brady, J. F. and Hong, J-Y. (1992). Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB Journal, 6, 737-744.
184. Yasui, N., Otani, K., Ishida, M., Mihara, K., Kondo, T., Osanai, T., Ohkubo, T., Sugawara, K., Kaneko, S., Fukushima, Y. (1994). Effects of thioridazine on the metabolism of trazodone. Neuropsychopharmacology, 10 (suppl. 3 part 2), 262S.
185. You, Y-W., Kim, S-H. and Lee, M-S. (1994). Coadministration of sertraline and haloperidol. Neuropsychopharmacology, 10 (suppl. 3 part 2), 200S.
186. Yue, O. Y., Svensson, J-O., Aim, C., Sjoqvist, F. and Sawe, J. (1989). Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. British Journal of Clinical Pharmacology, 28, 629-637.
187. Zussman, B. D., Davie, C. C., Fowles, S. E., Kumar, R., Lang, U., Wargenau, M. and Sourgens, H. (1995). Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. British Journal of Clinical Pharmacology, 39, 550P-551P.